Current concepts of renal hemodynamics in diabetes.
Glomerular hyperfiltration has long been recognized in insulin-dependent diabetes, and has been more recently recognized in patients with non-insulin dependent diabetes mellitus as well. Experimentally, glomerular hyperfiltration has been shown to result from elevations in the glomerular capillary blood flow and the glomerular capillary hydraulic pressure (PGC). Of the hemodynamic determinants of hyperfiltration, it is glomerular hypertension that is most damaging to the glomerulus. Experimental and clinical studies have confirmed that antihypertensive agents that lower PGC more consistently slow the progression of injury than do those that fail to control glomerular hypertension. The pathogenesis of diabetic hyperfiltration is multifactoral. Many mediators have been proposed, including changes due to the altered metabolic milieu, and alterations in endogenous levels of such vasoactive mediators as atrial natriuretic peptide, endothelial-derived relaxing factor, angiotensin II, prostaglandins, thromboxanes, and kinins, among others. It has more recently been suggested that local renal tissue levels, rather than circulating levels, play the more profound role in hemodynamic regulation. For example, the renin-angiotensin system (RAS) appears to be disproportionately active in the renal tissue, potentially explaining the renal vascular responsiveness to angiotensin-converting enzyme inhibition despite absence of systemic RAS activation. Little is yet known of the mechanisms by which glomerular hypertension leads to injury. Innovative new in vitro systems have been developed to address this question. These studies postulate that glomerular hemodynamic factors (shear stress, pulsatile flow) modify the growth and activity of glomerular component cells, inducing the expression of cytokines and other mediators, which then stimulate matrix production and promote structural injury.
Anderson
S
S
Division of Nephrology and Hypertension, Oregon Health Sciences University, Portland 97201, USA.
Vora
J P
JP
D000804:Angiotensin II / Q000502:physiology; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000502:physiology; D002196:Capillaries / Q000503:physiopathology; D003921:Diabetes Mellitus, Experimental / Q000503:physiopathology*; D003922:Diabetes Mellitus, Type 1 / Q000503:physiopathology*; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology*; D003928:Diabetic Nephropathies / Q000503:physiopathology*; D005919:Glomerular Filtration Rate; D006439:Hemodynamics; D006801:Humans; D006977:Hypertension, Renal / Q000503:physiopathology; D007668:Kidney / Q000098:blood supply* / Q000503:physiopathology; D007678:Kidney Glomerulus / Q000098:blood supply; D007705:Kinins / Q000502:physiology; D009129:Muscle Tonus; D009131:Muscle, Smooth, Vascular / Q000503:physiopathology; D011453:Prostaglandins / Q000502:physiology; D012039:Regional Blood Flow; D012079:Renal Circulation; D012084:Renin-Angiotensin System; D013931:Thromboxanes / Q000502:physiology
D007705:Kinins; D011453:Prostaglandins; D013931:Thromboxanes; D000804:Angiotensin II; D009320:Atrial Natriuretic Factor